

Danish oxygen robot is on its way to hospitals in eight European countries

25th of February 2019



After nine years of public-private cooperation the automatic oxygen robot, O2matic, is finally CE marked.

More than 250 million people suffer from the lung-disease Chronic Obstructive Pulmonary Disease, COPD, according to the latest numbers from the World Health Organization. About 0,1% of the population are so ill that they need oxygen treatment in their own home.

“After a long journey with several ups and downs, O2matic is now approved for hospital use. Our clinical results document that O2matic will improve the patient security at hospitals through continuous monitoring of the patients and at the same time adjust an optimal oxygen level. O2matic take over manual control from nurses and reduce the risk for unintended incidents. We would not have made it without help from the Fund of Innovation,” says Okan Ilker Grgen, CEO in O2matic ApS.

O2matic is developed in Denmark and produced by several production companies in the southern Zealand. Beside CE marking, the company has also signed a distribution contract with the world's largest oxygen supplier, Linde AG, which will sell O2matic in Central and Southern Europe:

“The interest in O2matic is very large. Customers have been waiting for O2matic and as soon as we have received our CE marking, the first units are on their way to hospitals in Denmark, Germany, France, England, Italy, Spain, Poland and Switzerland. We are now developing the next version of the product that will treat the patients in their own home and monitor them through telemedicine” says Farzad Saber, CPO in O2matic ApS.

Next step is home treatment through telemedicine

However, the work to create a better and safer treatment of COPD does not stop here for the Medtech company O2matic. COPD patients have a great need to get in touch with the healthcare sector and typically have many re-admissions.

According to the Ethics Council and the Lung association in Denmark, COPD patients are given a lower priority in the healthcare sector and do not receive the necessary attention. O2matic ApS must therefore, in cooperation with Danish Capital Region, Region Zealand, Medical Denmark A/S, and with the financial injection from the Innovation Fund, develop the world's first oxygen robot for home patients:

“When a COPD-patient is equipped with oxygen at home, they have an almost constant oxygen flow. These patients are only visited a few times a year and must therefore seek help themselves when they feel insecure. With an oxygen robot in their home with telemedicine monitoring, we offer patients greater security and expect to reduce patient’s acute need to contact the healthcare sector“ says Ejvind Frausing chief physician, Lung Medicine section, Hvidovre Hospital.

About O2matic

O2matic ApS was established in 2017 by the team, which since 2010 has been working on developing an automatic oxygen regulating system. O2matic ApS is ISO13485 certified.

Read more about the oxygen robot at www.o2matic.com

Contact:

O2matic ApS

Okan Ilker Görgen, CEO

Phone: +45 5051 4770;

Mail: okg@o2matic.com

Farzad Saber, CPO and member of the board

Phone: +45 2886 9200

Mail: fas@o2matic.com

Fund of Innovation

Jens Bomholt, Presse- and mediachef

Phone: +45 6190 5045

Mail: jens.bomholt@innofond.dk